Skip to main content
SpringerLink
Log in

Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis

  • Systematic Review
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

A Correction to this article was published on 18 August 2023

This article has been updated

Abstract

Introduction

The worldwide prevalence of chronic kidney disease (CKD) has significantly increased in the past decades. Scientific reports have shown CKD to be an enhancing risk factor for the development of cardiovascular disease (CVD), which is the leading cause of premature death in patients with CKD. Clinical practice guidelines are ambiguous in view of the use of antiplatelet drugs in patients with CKD because patients with moderate-to-severe CKD were often excluded from clinical trials evaluating the efficacy and safety of anticoagulants and antiplatelet agents. In this analysis, we aimed to systematically assess the adverse cardiovascular and bleeding outcomes that were observed with ticagrelor versus clopidogrel use in patients with CKD and cardiovascular disease.

Methods

Electronic databases including Web of Science, Google Scholar, http://www.ClinicalTrials.gov, Cochrane database, EMBASE, and MEDLINE were carefully searched for English-based articles comparing ticagrelor with clopidogrel in patients with CKD. Adverse cardiovascular outcomes and bleeding events were the endpoints in this study. The latest version of the RevMan software (version 5.4) was used to analyze the data. Risk ratios (RR) with 95% confidence intervals (CI) were used to represent the data post analysis.

Results

A total of 15,664 participants were included in this analysis, whereby 2456 CKD participants were assigned to ticagrelor and 13,208 CKD participants were assigned to clopidogrel. Our current analysis showed that major adverse cardiac events (MACEs) (RR: 0.85, 95% CI: 0.71–1.03; P = 0.09), all-cause mortality (RR: 0.82, 95% CI: 0.57– 1.18; P = 0.29), cardiovascular death (RR: 0.83, 95% CI: 0.56–1.23; P = 0.35), myocardial infarction (RR: 0.87, 95% CI: 0.70–1.07; P = 0.19), ischemic stroke (RR: 0.80, 95% CI: 0.58–1.11; P = 0.18), and hemorrhagic stroke (RR: 1.06, 95% CI: 0.38–2.99; P = 0.91) were not significantly different in CKD patients who were treated with ticagrelor versus clopidogrel. Thrombolysis in myocardial infarction (TIMI)-defined minor (RR: 0.89, 95% CI: 0.52–1.53; P = 0.68) and TIMI major bleeding (RR: 1.10, 95% CI: 0.69–1.76; P = 0.67) were also not significantly different. However, bleeding defined according to the academic research consortium (BARC) bleeding type 1 or 2 (RR: 1.95, 95% CI: 1.13–3.37; P = 0.02) and BARC bleeding type 3 or 5 (RR: 1.70, 95% CI: 1.17–2.48; P = 0.006) were significantly higher with ticagrelor.

Conclusions

When compared with clopidogrel, even though ticagrelor was not associated with higher risk of adverse cardiovascular outcomes in these patients with CKD, it was associated with significantly higher BARC bleeding. Therefore, the safety outcomes of ticagrelor still require further evaluation in patients with CKD. Nevertheless, this hypothesis should only be confirmed with more powerful results that could usually only be achieved using large-scale randomized trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Change history

References

  1. Hoerger TJ, Simpson SA, Yarnoff BO, et al. The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative. Am J Kidney Dis. 2015;65(3):40311.

  2. Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. US Department of Health and Human Services, Centers for Disease Control and Prevention. https://www.cdc.gov/kidneydisease/publications-resources/2019-nationalfacts.html. Accessed 12 Aug 2019.

  3. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858.

  4. Song K-K, Zhao D-L, Wang Y-D, et al. Analysis of factors associated with death in maintenance hemodialysis patients: a multicenter study in China. Chin Med J (Engl). 2017;130(8):885–91.

    Article  CAS  PubMed  Google Scholar 

  5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.

  6. Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int Suppl. 2005;99:S25–9 (MEDLINE: 16336573).

    Article  CAS  Google Scholar 

  7. Shrivastava A, Nath RK, Mahapatra HS, et al. Ultra-low CONtraSt PCI vs conVEntional PCI in patients of ACS with increased risk of CI-AKI (CONSaVE-AKI). Indian Heart J. 2022;74(5):363–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Giacoppo D, Matsuda Y, Fovino LN, et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2021;42(4):308–19.

    Article  CAS  PubMed  Google Scholar 

  9. El-Menyar A, Hussein H, Suwaidi JA. Coronary stent thrombosis in patients with chronic renal insufficiency. Angiology. 2010;61(3):297–303.

    Article  PubMed  Google Scholar 

  10. Jain N, Hedayati SS, Sarode R, Banerjee S, Reilly RF. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? Clin J Am Soc Nephrol. 2013;8(4):665–74.

    Article  CAS  PubMed  Google Scholar 

  11. Baber U, Mehran R, Kirtane AJ, et al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015;8(6):e001683.

    Article  PubMed  Google Scholar 

  12. Sharif-Askari FS, Sulaiman SAS, Sharif-Askari NS. Anticoagulation therapy in patients with chronic kidney disease. Adv Exp Med Biol. 2017;906:101–14.

    Article  CAS  Google Scholar 

  13. Tagarakis GI. Ticagrelor and prasugrel: two novel, most-promising antiplatelet agents. Recent Pat Cardiovasc Drug Discov. 2010;5(3):208–11.

    Article  CAS  PubMed  Google Scholar 

  14. Jacobsen MR, Engstrøm T, Torp-Pedersen C, et al. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction. Int J Cardiol. 2021;342:15–22.

    Article  PubMed  Google Scholar 

  15. Chen Y, Shaowen Tu, Chen Z, et al. Ticagrelor versus clopidogrel in patients with severe renal insufficiency undergoing PCI for acute coronary syndrome. J Interv Cardiol. 2022;31(2022):6476777.

    Google Scholar 

  16. Jain N, Phadnis MA, Hunt SL, et al. Comparative effectiveness and safety of oral p2y12 inhibitors in patients on chronic dialysis. Kidney Int Rep. 2021;6(9):2381–91.

    Article  PubMed  PubMed Central  Google Scholar 

  17. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056–67.

    Article  PubMed  Google Scholar 

  18. Lee C-H, Tsai T-H, Lin C-J, Hsueh S-K, Chung W-J, Cheng C-I. Efficacy and safety of ticagrelor compared with clopidogrel in patients with end-stage renal disease with acute myocardial infarction. Am J Cardiovasc Drugs. 2019;19(3):325–34.

    Article  CAS  PubMed  Google Scholar 

  19. Li Y-S, Wang S-H, Hwang S-J, Yang Y-H, Hsieh K-P. Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan. Br J Clin Pharmacol. 2022;88(1):145–54.

    Article  CAS  PubMed  Google Scholar 

  20. Mavrakanas TA, Kamal O, Charytan DM. Prasugrel and ticagrelor in patients with drug-eluting stents and kidney failure. Clin J Am Soc Nephrol. 2021;16(5):757–64.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Roh JW, Lee S-J, Kim B-K, et al. Ticagrelor vs clopidogrel in acute coronary syndrome patients with chronic kidney disease after new-generation drug-eluting stent implantation. Front Cardiovasc Med. 2022;8:707722.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kikkert WJ, van Geloven N, van der Laan MH, et al. The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications. J Am Coll Cardiol. 2014;63(18):1866–75.

    Article  PubMed  Google Scholar 

  23. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

    Article  PubMed  Google Scholar 

  24. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Lutz J, Jurk RNK. Platelets in advanced chronic kidney disease: two sides of the coin. Semin Thromb Hemost. 2020;46(3):342–56.

    Article  PubMed  Google Scholar 

  27. Xiaole S, Yan B, Wang L, Lv J, Cheng H, Chen Y. Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2019;20(1):309.

    Article  Google Scholar 

  28. Jain N, Corken A, Arthur JM, et al. Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease. Vascul Pharmacol. 2023;148:107143.

    Article  CAS  PubMed  Google Scholar 

  29. Tung Y-C, Chang C-J, Liu J-R, Chang S-H, Chan Y-H, Kuo C-T, See L-C. Outcomes after ticagrelor versus clopidogrel treatment in end-stage renal disease patients with acute myocardial infarction: a nationwide cohort study. Sci Rep. 2021;11(1):20826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Wu B, Lin H, Tobe RG, Zhang L, He B. Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials. J Comp Eff Res. 2018;7(3):281–91.

    Article  PubMed  Google Scholar 

  31. Park D-W, Kwon O, Jang J-S, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. Circulation. 2019;140(23):1865–77.

    Article  PubMed  Google Scholar 

  32. Kang H-J, Clare RM, Gao R, et al. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2015;169(6):899–905.e1.

  33. Sun Y, Li C, Zhang L, et al. Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients. Atherosclerosis. 2019;290:52–8.

    Article  CAS  PubMed  Google Scholar 

  34. Palmer SC, Micco LD, Razavian M, Craig JC, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;156(6):445–59.

    Article  PubMed  Google Scholar 

  35. Cho JY, Lee S-Y, Yun KH, et al. Factors related to major bleeding after ticagrelor therapy: results from the TICO trial. J Am Heart Assoc. 2021;10(7):e019630.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Graham CA, Tan MK, Chew DP, et al. Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT). Heart Vessels. 2022;37(8):1291–8.

    Article  PubMed  Google Scholar 

  37. Gragnano F, Moscarella E, Calabro P, et al. Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. Intern Emerg Med. 2021;16(2):379–87.

    Article  PubMed  Google Scholar 

  38. Wang Y, Yang Na, Suo M, et al. In-hospital outcomes of ticagrelor versus clopidogrel in high bleeding risk patients with acute coronary syndrome: findings from the CCC-ACS project. Thromb Res. 2022;216:43–51.

    Article  CAS  PubMed  Google Scholar 

  39. Wang H-Y, Li Yi, Xiao-Ming Xu, et al. Impact of baseline bleeding risk on efficacy and safety of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention. Chin Med J (Engl). 2018;131(17):2017–24.

    Article  CAS  PubMed  Google Scholar 

  40. Mainous AG, Tanner RJ, Shorr RI, Limacher MC. Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011–2012. J Am Heart Assoc. 2014;3(4):e000989.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Stuntz M, Bernstein B. Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012–2015. Prev Med Rep. 2016;28(5):183–6.

    Google Scholar 

Download references

Acknowledgements

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author information

Author notes

  1. Yinxue Guo and Pingyu Ge are co-first authors.

Authors and Affiliations

  1. Department of Nephrology, Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, Guizhou, People’s Republic of China

    Yinxue Guo, Ziju Li, Jingxia Xiao & Lirui Xie

  2. Department of Urology, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, 550001, Guizhou, People’s Republic of China

    Pingyu Ge

Authors
  1. Yinxue Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pingyu Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ziju Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jingxia Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lirui Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yinxue Guo.

Ethics declarations

Funding

No external funding was used in the preparation of this manuscript.

Conflict of interest

The authors Yinxue Guo, Pingyu Ge, Ziju Li, Jingxia Xiao and Lirui Xie declare that they have no competing interests.

Ethical approval

This meta-analysis is based on previously published studies and does not contain any studies with human participants or animals performed by any of the authors. Therefore, no ethical approval was required.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Code availability

Not applicable.

Data availability statement

All data generated or analyzed during this study are included in this published article. References have been provided. The full text articles containing those data can be obtained from electronic databases including PubMed, EMBASE, Web of Science and so on.

Authors’ contributions

Yinxue Guo, Pingyu Ge, Ziju Li, Jingxia Xiao, and Lirui Xie were responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. Yinxue Guo and Pingyu Ge wrote the final draft. All the authors approved the final manuscript as it has been written.

Additional information

The original online version of this article was revised to correct author affiliation 1.

Supplementary Information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, Y., Ge, P., Li, Z. et al. Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis. Am J Cardiovasc Drugs 23, 533–546 (2023). https://doi.org/10.1007/s40256-023-00600-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-023-00600-w

Search

Navigation